What we had was a massive correction below any fair value. Boom and then bust cycles. So the last rung down to 1.10 was simply exhaustion, completely oversold. And, there was always a good feeling what was seen was artifact: recall Stoll's latest two talks.
It seems to me the stock traded around 3 dollars a share after the hold was initiated and the stock stabilized around three bucks for many months. And the news is better now because of the artifact? not simply finding a safe dose to avoid some toxic change, a new ampakine is months away from clinical trials(CX701), new scientific models show high impact effects: Stoll is further along in negotiating a high impact deal. I think, with a just a little imagination, COR will be trading b/w 3 and 4 prior to the FDA decision--proably closer to 4.
Market Data 
Markets 
AI
